Stocks Health care JAZZ
NASDAQ · Health careJazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc brought in $4.7B of revenue over the twelve months to September 30, 2026, up 13.5% from a year earlier. Net income was $206M, a net margin of 4.4%. Operating cash flow minus capital spending left $1.3B of free cash flow in fiscal 2025. At September 30, 2026 it held $2B in cash against $5.6B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 2, 2026.
Key facts about Jazz Pharmaceuticals plc
- Net worth
- Jazz Pharmaceuticals plc has a market value (market cap) of $15.9B at the latest share price, and shareholders' equity of $4.2B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $4.3B (+4.9% year on year), with a net loss of $356.1M. Over the 12 months to September 30, 2026: revenue $4.7B, net income $206M.
- Cash flow
- In fiscal 2025 operations brought in $1.4B of cash; after $58.8M of capital spending, free cash flow was $1.3B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 2, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Jazz Pharmaceuticals plc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Jazz Pharmaceuticals plc does
Jazz Pharmaceuticals plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker JAZZ.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $4.3B | -$356.1M | -$5.84 | $1.3B |
| 2024 | $4.1B | $560.1M | $8.65 | $1.4B |
| 2023 | $3.8B | $414.8M | $6.10 | $1.1B |
| 2022 | $3.7B | -$224.1M | -$3.58 | $1.2B |
| 2021 | $3.1B | -$329.7M | -$5.52 | $750.9M |
| 2020 | $2.4B | $238.6M | $4.22 | $884.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where JAZZ ranks in Health care
Latest SEC filings
What Jazz Pharmaceuticals plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 2, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 10% to $1.2B versus the same quarter last year; diluted EPS -$7.48 versus $4.08.
- November 2, 2026
- October 26, 2026
- October 9, 2026Executive or director change8-KJazz Pharmaceuticals announced that Chief Commercial Officer Samantha Pearce intends to retire by June 30, 2027, or upon the appointment of her successor.
- September 23, 2026Material agreement8-KJazz Pharmaceuticals repriced its $1,895,000,000 term loan facility and extended its maturity to May 5, 2033.
- September 15, 2026
- August 31, 2026
- August 25, 2026Other event 8-K
- August 10, 2026
What is JAZZ worth? A DCF from its reported cash flow
Insider trades
What the people running Jazz Pharmaceuticals plc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $25.2M worth of shares in the last 90 days and bought none on the open market. Most of the selling (99%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 4, 2026 | Carr PatriciaSVP, Chief Accounting Officer | Exercised options | 1,250 | $175K |
| November 4, 2026 | Carr PatriciaSVP, Chief Accounting Officer | Sold | 1,250 | $289.2K |
| November 4, 2026 | Carr PatriciaSVP, Chief Accounting Officer | Sold | 163 | $37.7K |
| November 3, 2026 | Gala Renee DPresident & CEO, Director | Soldpre-planned (10b5-1) | 1,000 | $225.4K |
| November 2, 2026 | Cozadd Bruce CDirector | Soldpre-planned (10b5-1) | 6,000 | $1.3M |
| October 6, 2026 | Gala Renee DPresident & CEO, Director | Soldpre-planned (10b5-1) | 2,000 | $472.8K |
| October 1, 2026 | Cozadd Bruce CDirector | Soldpre-planned (10b5-1) | 6,000 | $1.4M |
| September 10, 2026 | Patil Neena MEVP & Chief Legal Officer | Soldpre-planned (10b5-1) | 1,200 | $289.1K |
Who owns JAZZ
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 7.4% | August 6, 2026 |
| Vanguard Capital Management13G, passive | 5.04% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 643 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 5,968,603 | +376,903 |
| Fmr LLC | 4,609,326 | +2,333,564 |
| Vanguard Portfolio Management LLC | 3,036,213 | +52,971 |
| Vanguard Capital Management LLC | 2,729,650 | +81,317 |
| Capital World Investors | 2,697,610 | +24,234 |
| Franklin Resources Inc | 2,040,250 | +81,310 |
| State Street Corp | 1,999,816 | +108,170 |
| Dimensional Fund Advisors LP | 1,713,592 | -181,623 |
| Fuller & Thaler Asset Management, Inc. | 1,638,544 | -37,598 |
| Bank of New York Mellon Corp | 1,578,013 | -101,358 |
| Aqr Capital Management LLC | 1,522,568 | +184,110 |
| Geode Capital Management, LLC | 1,483,031 | +245,414 |
| Ameriprise Financial Inc | 1,215,523 | -392,953 |
| Jpmorgan Chase & Co | 1,160,786 | -43,567 |
| Bank of America Corp | 1,136,091 | +121,291 |
| Citadel Advisors LLC | 1,006,676 | -252,768 |
| Swedbank AB | 968,092 | -24,016 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 799,297 | -85,904 |
| Millennium Management LLC | 763,880 | -498,631 |
| UBS Group AG | 756,865 | +399,662 |
Insiders
19 insiders reported holding 2,029,813 shares in total, about $498.2M at the last price.
| Holder | Shares |
|---|---|
| Mulligan SeamusDirector | 1,184,633 |
| Cozadd Bruce CDirector | 339,875 |
| Gala Renee DPresident & CEO, Director | 140,394 |
| Iannone RobertEVP, Global Head of R&D & CMO | 65,686 |
| Johnson Philip LEVP & Chief Financial Officer | 56,431 |
| Patil Neena MEVP & Chief Legal Officer | 47,671 |
| Pearce SamanthaEVP, Chief Commercial Officer | 47,131 |
| O'Keefe Kenneth WDirector | 25,811 |
| Henderson Mary ElizabethSVP, Technical Operations | 23,815 |
| Enright Patrick GDirector | 21,278 |
Questions about JAZZ
What does Jazz Pharmaceuticals plc do?
Jazz Pharmaceuticals plc is a company in the Health care sector, listed on NASDAQ as JAZZ. Its shares trade on NASDAQ under the ticker JAZZ.
What is Jazz Pharmaceuticals plc's net worth?
Jazz Pharmaceuticals plc has a market value (market cap) of $15.9B at the latest share price, and shareholders' equity of $4.2B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Jazz Pharmaceuticals plc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $206M on revenue of $4.7B, a net margin of 4.4%.
How much revenue does Jazz Pharmaceuticals plc make?
Over the twelve months to September 30, 2026 Jazz Pharmaceuticals plc reported revenue of $4.7B. That is 13.5% more than a year earlier.
When did Jazz Pharmaceuticals plc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 2, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 6, 2026.
When is Jazz Pharmaceuticals plc's next earnings report?
Jazz Pharmaceuticals plc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare JAZZ with
Follow JAZZ
Get an email when Jazz Pharmaceuticals plc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Jazz Pharmaceuticals plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.